| Current Price | $24.94 | Mkt Cap | $1.6B |
|---|---|---|---|
| Open | $25.20 | P/E Ratio | -15.78 |
| Prev. Close | $24.45 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $24.19 - $25.20 | Volume | 272,923 |
| 52-Wk Range | $11.42 - $41.93 | Avg. Daily Vol. | 1,031,941 |
Amylyx Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada.
| Current Price | $24.94 | Mkt Cap | $1.6B |
|---|---|---|---|
| Open | $25.20 | P/E Ratio | -15.78 |
| Prev. Close | $24.45 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $24.19 - $25.20 | Volume | 272,923 |
| 52-Wk Range | $11.42 - $41.93 | Avg. Daily Vol. | 1,031,941 |
The best Bull and Bear pitches based on recency and number of recommendations.
Read the most recent pitches from players about AMLX.
Recs
TMFjimhalley
(< 20)
Submitted: 9/8/2022 7:01:13 PM :
Start Price:
$27.40
NASDAQ:AMLX Score:
+15.57
Expectations for its ALS drug have sent the stock soaring, but the company has a long way to go to be profitable.
Find the members with the highest scoring picks in AMLX.
HDTVBG (< 20) Score: +50.64
The Score Leader is the player with the highest score across all their picks in AMLX.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| TMFjimhalley | < 20 | 9/9/2022 |
|
3W | $27.40 | -9.31% | +6.27% | +15.57 | 1 Comment | |
| TMFGBudwell | < 20 | 5/15/2023 |
|
5Y | $28.13 | -11.66% | +3.82% | -15.48 | 0 Comment | |
| TMFang4apples | 26.41 | 9/9/2022 |
|
NS | $29.84 | -16.71% | +5.66% | -22.37 | 0 Comment | |
| ababrmon | 66.36 | 3/15/2023 |
|
5Y | $33.00 | -24.70% | +10.78% | -35.48 | 0 Comment | |
| oldlumike | 29.16 | 10/6/2022 |
|
5Y | $32.35 | -23.18% | +13.92% | -37.11 | 0 Comment | |
| oldvolvoguy | 27.55 | 6/3/2022 |
|
3Y | $11.79 | +110.77% | +4.15% | -106.62 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
